About Aditxt, Inc.
Aditxt, Inc. is a biotechnology company that discovers and develops immunotherapy products for immune health, precision health, population health, women's health, and neurologic health. The company develops AditxtScore, a personalized immune profiling technology that enables individuals to understand and monitor their immune response profiles, and Apoptotic DNA Immunotherapy, a nucleic acid-based immunosuppressive technology designed to induce immune tolerance for organ transplantation, autoimmune diseases, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt also develops ADI-100 for skin grafting and related applications. The company operates subsidiary Adimune and maintains license agreements with Loma Linda University and Stanford University. Aditxt was incorporated in 2017 and is headquartered in Mountain View, California, United States.